-
1
FDA approval for CAR T therapy at University of Colorado Anschutz.
-
2
Targets CD64 protein on AML cells.
-
3
Phase 1 trial to assess safety and dosage.
-
4
Enrollment of adults with relapsed/refractory AML.
-
5
Program emphasizes academic center's capability in cell therapy development.
-
6
Potential future pediatric trial planned for
-
7
Aims to improve treatment options for aggressive cancers.
Original Source(s)
Related Content
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...
by ALISON RASH
April 15, 2026
-
8 min
From Spectra to Structure: An Interview with Novogaia’s Tess Bevers
Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery
by Henry Thomas
April 15, 2026
-
10 min
Mass Spec Roundup: From Masterpieces to Microplastics
Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment
April 15, 2026
-
6 min
